JP5807994B2 - アレルギー治療のための核酸 - Google Patents

アレルギー治療のための核酸 Download PDF

Info

Publication number
JP5807994B2
JP5807994B2 JP2015517226A JP2015517226A JP5807994B2 JP 5807994 B2 JP5807994 B2 JP 5807994B2 JP 2015517226 A JP2015517226 A JP 2015517226A JP 2015517226 A JP2015517226 A JP 2015517226A JP 5807994 B2 JP5807994 B2 JP 5807994B2
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
allergen
protein
cry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015517226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521467A (ja
JP2015521467A5 (enExample
Inventor
ウィリアム ハール，
ウィリアム ハール，
テリー ハイラント，
テリー ハイラント，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of JP2015521467A publication Critical patent/JP2015521467A/ja
Publication of JP2015521467A5 publication Critical patent/JP2015521467A5/ja
Application granted granted Critical
Publication of JP5807994B2 publication Critical patent/JP5807994B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2015517226A 2012-06-15 2012-06-15 アレルギー治療のための核酸 Active JP5807994B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015119893A Division JP6088584B2 (ja) 2015-06-15 2015-06-15 アレルギー治療のための核酸

Publications (3)

Publication Number Publication Date
JP2015521467A JP2015521467A (ja) 2015-07-30
JP2015521467A5 JP2015521467A5 (enExample) 2015-09-10
JP5807994B2 true JP5807994B2 (ja) 2015-11-10

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517226A Active JP5807994B2 (ja) 2012-06-15 2012-06-15 アレルギー治療のための核酸

Country Status (20)

Country Link
US (3) US9744230B2 (enExample)
EP (2) EP3808361A1 (enExample)
JP (1) JP5807994B2 (enExample)
KR (2) KR102107646B1 (enExample)
CN (2) CN107937423A (enExample)
AU (3) AU2012382406B2 (enExample)
BR (1) BR112014031327B1 (enExample)
CA (1) CA2876824C (enExample)
CY (1) CY1123769T1 (enExample)
DK (1) DK2861240T3 (enExample)
ES (1) ES2831723T3 (enExample)
HR (1) HRP20201815T1 (enExample)
HU (1) HUE052481T2 (enExample)
IL (4) IL236174B (enExample)
LT (1) LT2861240T (enExample)
PL (1) PL2861240T3 (enExample)
PT (1) PT2861240T (enExample)
RS (1) RS61098B1 (enExample)
SI (1) SI2861240T1 (enExample)
WO (1) WO2013187906A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
NZ707615A (en) 2012-10-30 2019-01-25 Aravax Pty Ltd Novel immunotherapeutic molecules and uses thereof
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
EP3157558A2 (en) * 2014-06-23 2017-04-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (en) * 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) * 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
EP3779443A4 (en) * 2018-04-06 2022-05-04 Slsbio Co., Ltd. NEW IMMUNOGLOBULIN E EPITOPE, BINDING ANTIBODY AND KIT FOR THE ANALYSIS OF IMMUNOGLOBULIN E IN A SAMPLE CONTAINING IT
WO2019216394A1 (ja) * 2018-05-11 2019-11-14 アステラス製薬株式会社 ダニアレルギー治療のための核酸
CA3099505A1 (en) * 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating crustacean allergy
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
US11766477B2 (en) 2019-01-23 2023-09-26 Societe Des Produits Nestle S.A. Methods for making mixed allergen compositions
CN113631231A (zh) * 2019-03-13 2021-11-09 普梭梅根公司 用于过敏治疗的基于表位的方法和克罗恩病的抑制剂
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
CN117795081A (zh) * 2021-08-06 2024-03-29 花王株式会社 利用snare的核酸构建体
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
AU5668194A (en) * 1992-11-12 1994-06-08 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
CA2241918C (en) 1995-12-29 2008-12-02 University Of Arkansas Peanut allergens and methods
CA2258125C (en) 1996-06-14 2010-11-23 Meiji Milk Products Co., Ltd. T-cell epitope peptides
US20020142978A1 (en) * 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
WO2002074250A2 (en) 2001-03-16 2002-09-26 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
ES2404689T3 (es) * 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
US20090304738A1 (en) 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
WO2007024026A1 (ja) * 2005-08-25 2007-03-01 Taiho Pharmaceutical Co., Ltd. Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
EP2331568B1 (en) * 2008-09-10 2014-09-03 ITH Immune Therapy Holdings AB Treating inflammatory conditions
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (en) * 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs

Also Published As

Publication number Publication date
US20160271245A1 (en) 2016-09-22
RS61098B1 (sr) 2020-12-31
AU2019250227A1 (en) 2019-11-07
JP2015521467A (ja) 2015-07-30
US20220081474A1 (en) 2022-03-17
CN104519896A (zh) 2015-04-15
EP2861240B1 (en) 2020-09-09
IL236174B (en) 2019-11-28
ES2831723T3 (es) 2021-06-09
AU2012382406A2 (en) 2015-04-16
CN104519896B (zh) 2017-11-10
US20180009857A1 (en) 2018-01-11
IL236174A0 (en) 2015-01-29
IL270260B (en) 2020-08-31
PL2861240T3 (pl) 2021-07-05
DK2861240T3 (da) 2020-09-28
WO2013187906A1 (en) 2013-12-19
PT2861240T (pt) 2020-11-09
CY1123769T1 (el) 2022-05-27
EP2861240A4 (en) 2016-03-16
AU2018200625B2 (en) 2019-09-19
KR102107646B1 (ko) 2020-05-08
AU2018200625A1 (en) 2018-02-15
US10072053B2 (en) 2018-09-11
SI2861240T1 (sl) 2021-04-30
HRP20201815T1 (hr) 2021-02-19
LT2861240T (lt) 2021-01-25
CA2876824A1 (en) 2013-12-19
KR102386481B1 (ko) 2022-04-14
KR20150032286A (ko) 2015-03-25
AU2012382406A1 (en) 2014-12-18
CA2876824C (en) 2020-07-21
BR112014031327A2 (pt) 2017-06-27
IL270262A (en) 2019-12-31
CN107937423A (zh) 2018-04-20
AU2019250227B2 (en) 2021-10-21
IL270261B (en) 2021-03-25
BR112014031327B1 (pt) 2022-02-01
KR20200047792A (ko) 2020-05-07
EP2861240A1 (en) 2015-04-22
EP3808361A1 (en) 2021-04-21
US9744230B2 (en) 2017-08-29
AU2012382406B2 (en) 2017-12-07
HUE052481T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
CN104519896B (zh) 用于治疗变态反应的核酸
US20190298821A1 (en) Nucleic Acids for Treatment of Peanut Allergies
JP5399895B2 (ja) ワクチン担体
JP6353510B2 (ja) アレルギー治療のための核酸
US20160185831A1 (en) Nucleic acids for treatment of allergies
JP6148088B2 (ja) アレルギー治療に用いるカベイラクサ（Ｐａｒｉｅｔａｒｉａｊｕｄａｉｃａ）の脂質輸送タンパク質ファミリーに属する低アレルギー誘導性のキメラタンパク質
JP6088584B2 (ja) アレルギー治療のための核酸
EP2281836A1 (en) Hybrid proteins from Parietaria judaica major allergens and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150615

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150615

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150903

R150 Certificate of patent or registration of utility model

Ref document number: 5807994

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250